A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation

BACKGROUND: The purpose of this study was to test the efficacy and safety of daclizumab (DZM) versus anti-thymocyte globulin (ATG) as a component of induction therapy in heart transplant recipients. METHODS: Thirty heart transplant patients were randomized to receive either ATG or DZM during inducti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mullen, John C, Kuurstra, Emily J, Oreopoulos, Antigone, Bentley, Michael J, Wang, Shaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120716/
https://www.ncbi.nlm.nih.gov/pubmed/25093077
http://dx.doi.org/10.1186/2047-1440-3-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120716/
https://www.ncbi.nlm.nih.gov/pubmed/25093077
http://dx.doi.org/10.1186/2047-1440-3-14

Ejemplares similares